ModernMedicine Resource Center More Topics

Hot Topics in Prostate Cancer

Genetic testing for prostate Ca: What the experts sayA recently published statement provides an evidence-based, consensus-driven framework on the role of genetic testing for determining prostate cancer risk, screening, and management.
Liquid biopsy tests for prostate Ca show low congruenceThe findings “[raise] the specter that patients could potentially receive different treatments depending on the cell-free DNA platform,” authors of a recent research letter write.
Biennial vs. annual prostate biopsies: What the data showAmong men undergoing active surveillance for low-risk prostate cancer, biennial biopsies appear to be an acceptable alternative to annual biopsies.
Prostate Ca test linked to reduction in biopsiesPatients with non-suspicious digital rectal exam findings and total PSA in the 4.0- to 10.0-ng/mL range are far less likely to be biopsied if they’ve undergone Prostate Health Index (phi) testing than if they don’t.
PSA screening: What do you tell primary care docs?We asked several urologists about whether they advocate for PSA screening to primary care physicians in their area.
Pair of genes may predict prostate cancer metastasisOverexpression of a specific pair of genes might provide early warning of prostate cancer patients’ likelihood of progressing to metastatic disease.
Why you need to better counsel PCa patients on sexual functionThere’s a troubling disconnect between low-risk prostate cancer patients’ desire to preserve sexual function and the treatment choices they and their doctors often make.
[Quiz]: Defect observed during RARPDuring a robot-assisted laparoscopic radical prostatectomy case, you notice a large defect medial to the inferior epigastric artery on the right side after taking down the bladder. Similar defect is noted on the left side.
Immune content linked to aggressive PCa outcomesThe level of immune response in prostate cancer may predict a patient’s response to radiation therapy, risk of disease recurrence, and survival outcomes, according to results of a recent analysis of prostate tumors.
Antiandrogen’s role may extend to non-metastatic CRPCTop-line results from a large phase III trial support a potential role for enzalutamide (XTANDI) as treatment for non-metastatic castration-resistant prostate cancer.